Richman, J., Ring, A., Dowsett, M., & Sestak, I. (2020). Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. Breast Cancer Res Treat.
Style de citation ChicagoRichman, Juliet, Alistair Ring, Mitch Dowsett, et Ivana Sestak. "Clinical Validity of Clinical Treatment Score 5 (CTS5) for Estimating Risk of Late Recurrence in Unselected, Non-trial Patients With Early Oestrogen Receptor-positive Breast Cancer." Breast Cancer Res Treat 2020.
Style de citation MLARichman, Juliet, Alistair Ring, Mitch Dowsett, et Ivana Sestak. "Clinical Validity of Clinical Treatment Score 5 (CTS5) for Estimating Risk of Late Recurrence in Unselected, Non-trial Patients With Early Oestrogen Receptor-positive Breast Cancer." Breast Cancer Res Treat 2020.